Page 3 - Aipsc News Today

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) has received an average recommendation of “Moderate Buy” from the eleven ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold recommendation and nine have assigned a buy recommendation to the company. The average 12 month price […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) – Analysts at Chardan Capital lifted their FY2023 earnings estimates for shares of Century Therapeutics in a research note issued on Wednesday, March 22nd. Chardan Capital analyst G. Livshits now forecasts that the company will post earnings per share of ($1.80) for the year, up from their prior […]

Chardan Capital restated their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a research note published on Wednesday, Benzinga reports. The brokerage currently has a $19.00 price target on the stock. IPSC has been the topic of a number of other reports. HC Wainwright dropped their target price on Century Therapeutics […]

Chardan Capital reiterated their buy rating on shares of Century Therapeutics (NASDAQ:IPSC – Get Rating) in a research report released on Wednesday, Benzinga reports. The brokerage currently has a $19.00 price objective on the stock. IPSC has been the subject of several other research reports. HC Wainwright dropped their price target on shares of Century […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) insider Luis Borges sold 63,616 shares of Century Therapeutics stock in a transaction dated Tuesday, March 21st. The stock was sold at an average price of $3.77, for a total value of $239,832.32. Following the transaction, the insider now directly owns 43,750 shares in the company, valued at […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) insider Luis Borges sold 15,597 shares of Century Therapeutics stock in a transaction dated Thursday, March 23rd. The shares were sold at an average price of $3.55, for a total transaction of $55,369.35. Following the completion of the sale, the insider now owns 249,083 shares in the company, […]

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) insider Luis Borges sold 15,597 shares of the stock in a transaction on Thursday, March 23rd. The shares were sold at an average price of $3.55, for a total value of $55,369.35. Following the transaction, the insider now directly owns 249,083 shares of the company’s stock, valued at […]

Induced pluripotent stem cells (iPSC) are a promising avenue by which cellular therapies may be enhanced. They also represent massive potential in drug tests and gene therapies. Sino Biological has a vast range of iPSC cytokines for R&D.

Century Therapeutics, Inc. (NASDAQ:IPSC – Get Rating) has been given a consensus rating of “Moderate Buy” by the seven ratings firms that are covering the company, Marketbeat reports. One research analyst has rated the stock with a hold rating and six have assigned a buy rating to the company. The average 12-month price objective among […]

More than 70% of stem cell lines derived from human skin cells have damage to their DNA that could compromise their use in research and cell-based therapies.